Therapeutic Advances in Hematology

Papers
(The H4-Index of Therapeutic Advances in Hematology is 13. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-04-01 to 2024-04-01.)
ArticleCitations
Mitapivat, a novel pyruvate kinase activator, for the treatment of hereditary hemolytic anemias30
Assessment of thrombotic risk during long-term treatment of immune thrombocytopenia with fostamatinib26
Venetoclax-containing regimens in acute myeloid leukemia24
B-cell maturation antigen (BCMA) in multiple myeloma: the new frontier of targeted therapies23
Current evidence and the emerging role of eltrombopag in severe aplastic anemia21
Bortezomib in autoimmune hemolytic anemia and beyond21
Thrombopoietin receptor agonist for treatment of immune thrombocytopenia in pregnancy: a narrative review19
Safety and efficacy of pegcetacoplan in paroxysmal nocturnal hemoglobinuria18
Ferumoxytol for the treatment of iron deficiency and iron-deficiency anemia of pregnancy17
Primary central nervous system lymphoma in the United States, 1975–201714
Expression of γ-globin genes in β-thalassemia patients treated with sirolimus: results from a pilot clinical trial (Sirthalaclin)14
Clinical features ofDDX41mutation-related diseases: a systematic review with individual patient data14
The evolving role of Bruton’s tyrosine kinase inhibitors in chronic lymphocytic leukemia13
International consensus recommendations on the management of people with haemophilia B13
Voxelotor: alteration of sickle cell disease pathophysiology by a first-in-class polymerization inhibitor13
Current and emerging treatment options in primary mediastinal B-cell lymphoma13
0.04579496383667